Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515318 | 0.84 | CCR1 (0.43) | CCR1CCR5CCR8SMN1; SMN2PSMD14 | |
| SCHEMBL5391951 | 0.78 | MAPT (0.33) | SMN1; SMN2KDM4EMAPTNPC1ALDH1A1 | |
| SCHEMBL4473450 | 0.77 | PDGFRB (0.41) | RIPK2 | |
| SCHEMBL4475122 | 0.76 | KDM4E (0.32) | KDM4EMAPTNCF1 | |
| SCHEMBL21834220 | 0.76 | PRKCI (0.37) | KDM4EMAPTNCF1 | |
| SCHEMBL8490190 | 0.76 | NCF1 (0.53) | KDM4EMAPTALDH1A1HPGDTSHR | |
| SCHEMBL4455983 | 0.76 | AXL (0.37) | KDM4EMAPTALDH1A1HPGDMAPK1 | |
| SCHEMBL28351340 | 0.73 | TGFBR1 (0.37) | KDM4EMAPTALDH1A1HPGDTSHR | |
| Water SCHEMBL2007545 | 0.72 | NCF1 (0.54) | CCR1CCR5CCR8SMN1; SMN2PSMD14 | |
| Water SCHEMBL27574083 | 0.72 | NCF1 (0.54) | CCR1CCR5CCR8SMN1; SMN2PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563713-A | 4-phenyl substituted isoxazole compound and application thereof in antihistamine medicine | 王兴理 | 2019-12-13 | — | — | CN | claimed |
| CN-110563713-A | 4-phenyl substituted isoxazole compound and application thereof in antihistamine medicine | 王兴理 | 2019-12-13 | — | — | CN | disclosed |
| US-20160095897-A1 | PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2016-04-07 | — | — | US | disclosed |
| EP-2988773-A2 | PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS | Institut National De La Recherche Agronomique (INRA) (FR) | 2016-03-02 | — | — | EP | disclosed |
| US-9125861-B2 | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| CN-104507927-A | Cyclic azine compound, method for producing same, and organic electroluminescent element containing same | TOSOH CORP | 2015-04-08 | — | — | CN | disclosed |
| WO-2014173859-A2 | PAR-4 ANTAGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-10-30 | — | — | WO | disclosed |
| US-20140308296-A1 | PAR-1 Antagonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-10-16 | — | — | US | disclosed |
| US-8802623-B2 | PAR-1 antagonists for use in the treatment or prevention of influenza virus type A infections | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2014-08-12 | — | — | US | disclosed |
| CN-102711787-A | PAR1 antagonists for use in the treatment or prevention of influenza A virus infection | AGRONOMIQUE INST NAT RECH | 2012-10-03 | — | — | CN | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1511765-A4 | PAR-2-ACTIVATING PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING THE SAME | UNIV EDINBURGH (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222384-A1 | Par-2-activating peptide derivative and pharmaceutical composition using the same | UNIVERSITY OF EDINBURGH, THE (GB) | 2005-10-06 | — | — | US | disclosed |
| CN-1659183-A | Par-2-activating peptide derivative and pharmaceutical composition using the same | UNIV EDINBURGH (GB) | 2005-08-24 | — | — | CN | disclosed |
| EP-1511765-A1 | PAR-2-ACTIVATING PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING THE SAME | UNIVERSITY OF EDINBURGH (GB) | 2005-03-09 | — | — | EP | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003104268-A1 | PAR-2-ACTIVATING PEPTIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING THE SAME | THE UNIVERSITY OF EDINBURGH (GB) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CCR1 248/4885CCR5 701/4885CCR8 468/4885 |
| US-20050222384-A1 | Par-2-activating peptide derivative and pharmaceutical composition using the same | F2RL1, ADM2, PARN | CCR1 484/4885CCR5 952/4885CCR8 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.